Digital Diagnostics vs Ibex Medical Analytics
The two strongest regulatory records in diagnostics, at opposite ends of the autonomy spectrum. Digital Diagnostics holds the only United States authorisation for an autonomous diagnosis, where the system issues the diabetic retinopathy result and no physician reads the image, backed by the best pivotal evidence design in this index with equity built into it. Ibex flags cancer on a slide a pathologist still signs, with three cancer types in routine clinical use, peer reviewed publication behind the deployment scale and the most complete published certification set of any vendor here. Neither competes with the other clinically. Together they mark the two poles a buyer should keep distinct: a product that decides needs pivotal evidence in the population it will serve, and a product that assists needs to show clinicians do better with it.
- It is the only United States authorised instance of a diagnosis made without a clinician reading the image, with the best pivotal evidence design in this index behind it.
- Equity was an input to that trial design rather than a disclosure added afterwards, which is rare anywhere here.
- There is a reimbursement pathway for the workflow rather than a value argument, which decides whether a primary care clinic runs the test at all.
- The published certification set is the most complete of any vendor in this index, and deployment evidence is verifiable through third parties rather than vendor claims.
- Three cancer types are in routine clinical use worldwide, with peer reviewed publication behind the deployment scale and a conservative cleared indication.
- For a laboratory signing out cancer diagnoses, an authorised detection product with that assurance record is the higher bar.
Side by Side
| Axis | D Digital Diagnostics |
I Ibex Medical Analytics |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Diagnostics & Genomics page.
The two occupy opposite ends of the autonomy spectrum in diagnostics and that is the substance of the comparison: one issues a result with no clinician in the loop, the other flags suspicious tissue on a slide a pathologist signs. The evidence demanded should differ accordingly. Digital Diagnostics publishes no security attestation of any kind, and neither vendor publishes a business associate agreement template. Neither publishes subgroup performance beyond what the pivotal design captured, and in pathology staining and scanner variation between laboratories remains the largest uncontrolled variable.